<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>

<!-- This file generated using Python HTMLgen module. -->
<HEAD>
  <META NAME="GENERATOR" CONTENT="HTMLgen 2.2.2">
        <TITLE>Drug Interaction Knowledge Base 1.2</TITLE>

 <LINK rel=stylesheet href="html/HTMLgen.css" type="text/css" title="html/HTMLgen.css">
</HEAD>
<BODY BGCOLOR="#FFFFFF" TEXT="#000000" LINK="#0000FF" VLINK="#EE0000">
<span style="width: 60px"></span> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<H3>Drug Interaction Knowledge Base 1.2</H3>
<H2>fluoxetine_increases_auc_olanzapine</H2>
<HR>

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>

<!-- This file generated using Python HTMLgen module. -->
<HEAD>
  <META NAME="GENERATOR" CONTENT="HTMLgen 2.2.2">
        <TITLE></TITLE>

 <LINK rel=stylesheet href="html/HTMLgen.css" type="text/css" title="html/HTMLgen.css">
</HEAD>
<BODY BGCOLOR="#FFFFFF" TEXT="#000000" LINK="#0000FF" VLINK="#EE0000">
<b>You can go to DIKB assertion index here:</b>  
<A HREF="/dikb-evidence/index.html">DIKB assertion index</A>
<br><b>You can go to DIKB the home page here:</b>  
<A HREF="/dikb-evidence/front-page.html">DIKB Front Page</A>

<P>

<a name="
fluoxetine_increases_auc_olanzapine
"></a>
<b>Assertion:
fluoxetine increases_auc olanzapine
</b>
<BR>
<A NAME="Evidence"></A>
<P><TABLE border=2 cellpadding=4 cellspacing=1 width="100%">
<CAPTION align=top><STRONG>Evidence</STRONG></CAPTION>
<TR><TD Align=left ><STRONG>Evidence For (item 0)</STRONG></TD>
<TD Align=left ><STRONG>Evidence Type: </STRONG>EV_PK_DDI_NR</TD>
<TD Align=left ><STRONG>Pointer: </STRONG>http://www.ncbi.nlm.nih.gov/pubmed/12102620</TD>
<TD Align=left ><STRONG>Reviewer: </STRONG>boycer</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Quote: </STRONG><br>NOTE: The AUC_i/AUC value is from Table 1.<br><br>route of administration: oral<br><br>study duration: 8 days<br><br>population: 15 healthy subjects (11 male, 4 female), all nonsmokers; 13 Caucasian, 1 Hispanic, 1 Asian<br><br>tested for known CYP450 polymorphisms?<br>NO<br><br>ages: 23-40<br><br>description:<br>SUBJECTS: Subjects were nonsmokers who were of normal build and had no clinically significant abnormalities. Fifteen subjects (4 females and 11 males) completed the study. Thirteen subjects were Caucasian, 3 were Hispanic, and one was Asian. Ages ranged from 23 to 40 years (mean = 32 +/- 5 years). At admission, mean height was 173 +/- 10 cm and mean weight was 71 +/- 13 kg.<br><br>METHODS: The pharmacokinetics of 3 identical single therapeutic doses of olanzapine (5 mg) were determined in 15 healthy nonsmoking volunteers. The first dose of olanzapine was taken alone, the second given after a single oral dose of fluoxetine (60 mg), and the third given after 8 days of treatment with fluoxetine 60 mg, qd. There was an interval of 10 days between olanzapine doses of periods 1 and 2, and at least 15 days between olanzapine doses of periods 2 and 3. During each period, the volunteers remained in the clinical pharmacology unit for 24 hours following the administration of olanzapine.<br><br>RESULTS: After single coadministration of fluoxetine, the C_max and AUC_0-inf of olanzapine increased by 18%, whereas the total apparent clearance decreased by 15%.<br></TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>Assumptions: </STRONG></TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>increases_auc: </STRONG>1.18</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>object_dose: </STRONG>0.005</TD>
<TD Align=left ><STRONG>precip_dose: </STRONG>0.06</TD>
</TR>
<TR><TD Align=left ></TD>
<TD Align=left ><STRONG>numb_subj: </STRONG>15</TD>
</TR>
</TABLE><P>

<BR>

</BODY> </HTML>

<b>You can go to DIKB assertion index here:</b>  
<A HREF="/dikb-evidence/index.html">DIKB assertion index</A>
<br><b>You can go to DIKB the home page here:</b>  
<A HREF="/dikb-evidence/front-page.html">DIKB Front Page</A>

<P>

<BR><BR><a rel="license" href="http://creativecommons.org/licenses/by-nc-sa/3.0/"><img alt="Creative Commons License" style="border-width:0" src="http://i.creativecommons.org/l/by-nc-sa/3.0/88x31.png" /></a><br /><span xmlns:dct="http://purl.org/dc/terms/" href="http://purl.org/dc/dcmitype/Dataset" property="dct:title" rel="dct:type">Drug Interaction Knowledge Base (DIKB)</span> by <a xmlns:cc="http://creativecommons.org/ns#" href="http://www.dbmi.pitt.edu/person/richard-boyce-phd" property="cc:attributionName" rel="cc:attributionURL">Richard D. Boyce</a> is licensed under a <a rel="license" href="http://creativecommons.org/licenses/by-nc-sa/3.0/">Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License</a>.

<P><HR>
<span style="width: 60px"></span> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<IMG src="./images/blank.gif" height="22" width="66" alt="blank.gif"> 
<BR><IMG src="./images/logo.jpg" alt="logo.jpg" align="bottom">
<FONT SIZE="-1"><P>Copyright &#169 (c) 2005-2012 Richard David Boyce<BR>All Rights Reserved<BR>

Comments to author: <A HREF="mailto:&#114;d&#98;2&#48; &#97;t&#32;p&#105;t&#116; &#60;d&#111;t&#62; &#101;d&#117;">rdb20 at pitt <dot> edu</A><br>
Generated: Wed Jul 29, 2015 <BR><hr>
</FONT>
</BODY> </HTML>
